Robert A. Lustig

Robert A. Lustig

Auto-generated profile, based on publicly available information

Robert A. Lustig

Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2022 in Scientific Data
Verified
Journal Article
Open access
PDF file
Spyridon BakasSpyridon Bakas
Spyridon Bakas
CSChiharu Sako
Chiharu Sako
HAHamed Akbari
Hamed Akbari
MBMichel Bilello
Michel Bilello
ASAristeidis Sotiras
Aristeidis Sotiras
CDChristos Davatzikos
Christos Davatzikos
Glioblastoma is the most common aggressive adult brain tumor. Numerous studies have reported results from either private institutional data or publicly available datasets. However, current public datasets are limited in terms of: a) number of subjects, b) lack of consistent acquisition protocol, c) data quality, or d) accompanying clinical, demographic, and molecular information. Toward alleviating these limitations, we contribute the “University of Pennsylvania Glioblastoma Imaging, Genomics, and Radiomics” (UPenn-GBM) dataset, which describes the currently largest publicly available comprehensive collection of 630 patients diagnosed withde novoglioblastoma. The UPenn-GBM dataset includes (a) advanced multi-parametric magnetic resonance imaging scans acquired during routine clinical practice, at the University of Pennsylvania Health System, (b) accompanying clinical, demographic, and molecular information, (d) perfusion and diffusion derivative volumes, (e) computationally-derived and manually-revised expert annotations of tumor sub-regions, as well as (f) quantitative imaging (also known as radiomic) features corresponding to each of these regions. This collection describes our contribution towards repeatable, reproducible, and comparative quantitative studies leading to new predictive, prognostic, and diagnostic assessments.

1 December 2018 in Cancer Research
Verified
Journal Article
Closed access
PDF file
TLTianrun Liu
Tianrun Liu
HXHaineng Xu
Haineng Xu
MHMenggui Huang
Menggui Huang
WMWenjuan Ma
Wenjuan Ma
DSDeeksha Saxena
Deeksha Saxena
YFYi Fan
Yi Fan
Circulating tumor cells (CTC) are known to be present in the blood of patients with glioblastoma (GBM). Here we report that GBM-derived CTC possess a cancer stem cell (CSC)-like phenotype and contribute to local tumorigenesis and recurrence by the process of self-seeding. Genetic probes showed that mouse GBM-derived CTC exhibited Sox2/ETn transcriptional activation and expressed glioma CSC markers, consistent with robust expression of stemness-associated genes including SOX2, OCT4, and NANOG in human GBM patient-derived samples containing CTC. A transgenic mouse model demonstrated that CTC returned to the primary tumor and generated new tumors with enhanced tumorigenic capacity. These CTCs were resistant to radiotherapy and chemotherapy and to circulation stress-induced cell apoptosis. Single-cell RNA-seq analysis revealed that Wnt activation induced stemness and chemoresistance in CTC. Collectively, these findings identify GBM-derived CTC as CSC-like cells and suggest that targeting Wnt may offer therapeutic opportunities for eliminating these treatment-refractory cells in GBM. Significance: These findings identify CTCs as an alternative source for in situ tumor invasion and recurrence through local micrometastasis, warranting eradication of systemic "out-of-tumor" CTCs as a promising new therapeutic opportunity for GBM.

21 May 2014 in Journal of Adolescent and Young Adult Oncology
Verified
Journal Article
Open access
NLNataniel H. Lester-Coll
Nataniel H. Lester-Coll
CMChristopher B. Morse
Christopher B. Morse
HZHuifang A. Zhai
Huifang A. Zhai
SBStefan Both
Stefan Both
JGJill P. Ginsberg
Jill P. Ginsberg
CHChristine E. Hill-Kayser
Christine E. Hill-Kayser
Craniospinal irradiation (CSI) is associated with infertility risk for adolescent/young adult women. We explore two methods of reducing ovarian exposure: oophoropexy (surgical removal of the ovaries from the path of the X-ray beam) and proton therapy (to allow the beam to stop without exposing the ovaries/uterus). In the case discussed, oophoropexy followed by X-ray CSI reduced ovarian dose to that at which 50% of oocytes are expected to survive, and the patient appears to have viable oocytes; this technique did not reduce uterine dose. Proton therapy would have eliminated the ovarian and uterine dose and the need for oophoropexy.

8 November 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
FIFabio M. Iwamoto
Fabio M. Iwamoto
STShyam K. Tanguturi
Shyam K. Tanguturi
LNLakshmi Nayak
Lakshmi Nayak
TWTony Wang
Tony Wang
ADArati Desai
Arati Desai
DRDavid A. Reardon
David A. Reardon
Purpose: Radiotherapy may enhance antitumor immune responses by several mechanisms, including induction of immunogenic cell death. We performed a phase 2 study of pembrolizumab with re-irradiation in patients with recurrent glioblastoma. Patients and Methods: Sixty patients with recurrent glioblastoma received pembrolizumab with re-irradiation alone (cohort A, bevacizumab-naïve; n = 30) or with bevacizumab continuation (cohort B, n = 30). Dual primary endpoints, including the overall response rate and overall survival (OS) at either 12 (OS-12; cohort A) or 6 months (OS-6; cohort B), were assessed per cohort relative to historic benchmarks. Paired paraffin-embedded formalin-fixed tumor samples were assessed for immunologic biomarkers by IHC using digital quantification and co-detection-by-indexing (CODEX). Results: Study therapy was well tolerated, with most toxicities being grade ≤3. For cohort B, the primary endpoint of OS-6 was achieved (57%); however, survival was not improved for cohort A patients. The overall response rate was 3.3% and 6.7% for cohorts A and B, respectively. CODEX analysis of paired tumor samples from five patients revealed an increase of activated T cells in the tumor microenvironment after study therapy. Conclusions: Compared with historic controls, re-irradiation plus pembrolizumab seemed to improve survival among bevacizumab-refractory patients but not among bevacizumab-naïve patients. CODEX revealed evidence of intratumoral infiltration of activated immune effector cells. A randomized, properly controlled trial of PD-1 blockade plus re-irradiation is warranted to further evaluate this regimen for bevacizumab-refractory patients, but alternative approaches are needed for bevacizumab-naïve patients.

5 March 2019 in JMIR Perioperative Medicine
Verified
Journal Article
Open access
JGJorge Galvez
Jorge Galvez
MEMelanie Eisenhower
Melanie Eisenhower
WEWilliam England
William England
EWElicia Wartman
Elicia Wartman
ASAllan F. Simpao
Allan F. Simpao
MHMichelle Hribar
Michelle Hribar
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Proof-of-concept study to determine the feasibility of incorporating a virtual reality tour for children scheduled to receive radiation therapy. The secondary objective was to qualitatively describe each subject's virtual reality experience. Methods: Children ages 13 or older scheduled to receive proton radiation therapy were included in the study. Subjects watched the virtual reality tour of the radiation therapy facility with a child life therapist experienced in coaching children receiving radiation therapy and completed a survey after the tour. Results: Eight subjects consented for participation and 6 completed the virtual reality tour. All of the enrolled patients completed the virtual reality tour successfully. Two subjects did not complete the survey. Two subjects requested to pause the tour to ask questions about the facility. Five subjects said the virtual reality tour was helpful preparation before undergo proton radiation therapy. Subjects stated that the tour was helpful because ‘it showed me what’s to come’ and it was helpful to see ‘what it’s like to lay in the machine.’ One subject said ‘it made me feel less nervous.’ Six subjects stated that they would like to see this type of tour available for other areas of the hospital, such as diagnostic imaging rooms. None of the subjects experienced nausea or vomiting. Conclusions: The virtual reality video tour allowed patients to explore the treatment facility in a comfortable environment. Participants expressed that the tour was beneficial and would appreciate seeing other parts of the hospital in this way.

1 July 2016 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
CACarol L. Armstrong
Carol L. Armstrong
MFMichael J. Fisher
Michael J. Fisher
YLYimei Li
Yimei Li
RLRobert A. Lustig
Robert A. Lustig
JBJean B. Belasco
Jean B. Belasco
PPPeter C. Phillips
Peter C. Phillips